Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.
Fiche publication
Date publication
mai 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Pr BORG Christophe, Dr GODET Yann, Dr GALAINE Jeanne
Tous les auteurs :
Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C
Lien Pubmed
Résumé
Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.
Référence
Hum Vaccin Immunother. 2013 May;9(5):1073-7